Gene expression signature for classification of kidney tumors
AssigneesRosetta Genomics Ltd., Tel HaShomer Medical Research Infrastructure and Services Ltd.
InventorsNitzan Rosenfeld, Yael Spector, Eddie Friedman, Zohar Dotan, Shai Rosenwald
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy.
Claims8
A method for distinguishing between oncocytoma, clear cell renal cell carcinoma (RCC), papillary (chromaphil) RCC and chromophobe RCC in a human subject with renal cancer, the method comprising:
- (a) obtaining a kidney tumor sample from the human subject;
- (b) determining an expression profile in said sample of SEQ ID NOS:
- 1-24 by contacting the sample with probes that hybridize to each of SEQ ID NOS:
- 1-24, wherein each probe comprises the complement of one of SEQ ID NOs:
- 1-24, and wherein the probes are attached to a solid substrate;
- (c) comparing said expression profile to a reference threshold value by using a classifier algorithm;
- and
- (d) determining whether the human subject has oncocytoma, clear cell renal cell carcinoma (RCC), papillary (chromaphil) RCC or chromophobe RCC based on altered expression of SEQ ID NOS:
- 1-24 in the sample relative to the reference threshold value;
- wherein increased expression of SEQ ID NOS:
- 3, 5, 7, 9, 11, 12, 16, 18, 19 and 23 relative to the reference threshold is indicative of the presence of oncocytoma;
- wherein increased expression of SEQ ID NOS:
- 1, 2, 4, 6, 8, 10, 13-15, 17, 20-22 and 24 is indicative of the presence of chromophobe RCC;
- wherein increased expression of SEQ ID NOS:
- 3, 5-7, 9, 12 and 24 is indicative of the presence of clear cell RCC;
- and wherein increased expression of SEQ ID NOS:
- 1, 2, 4, 8, 10, 11 and 13-23 is indicative of the presence of papillary RCC.
A method for distinguishing between chromophobe RCC and oncocytoma in a human subject with renal cancer, the method comprising:
- (a) obtaining a kidney tumor sample from the human subject;
- (b) determining in said sample an expression profile of SEQ ID NOS:
- 1-24 by contacting the sample with probes that hybridize to each of SEQ ID NOS:
- 1-24, wherein each probe comprises the complement of one of SEQ ID NOs:
- 1-24, and wherein the probes are attached to a solid substrate;
- (c) comparing said expression profile to a reference threshold value;
- and
- (d) determining whether the human subject has oncocytoma or chromophobe RCC based on altered expression of SEQ ID NOS:
- 1-24 relative to the reference threshold value;
- wherein increased expression of SEQ ID NOS:
- 1, 2, 4, 6, 8, 10, 13-15, 17, 20-22 and 24 is indicative of the presence of chromophobe RCC;
- and wherein increased expression of SEQ ID NOS:
- 3, 5, 7, 9, 11, 12, 16, 18, 19 and 23 relative to the reference threshold is indicative of the presence of oncocytoma.
A method for distinguishing between clear cell RCC and papillary RCC in a human subject with renal cancer, the method comprising:
- (a) obtaining a kidney tumor sample from the human subject;
- (b) determining in said sample an expression profile of SEQ ID NOS:
- 1-24 by contacting the sample with probes that hybridize to each of SEQ ID NOS:
- 1-24, wherein each probe comprises the complement of one of SEQ ID NOs:
- 1-24, and wherein the probes are attached to a solid substrate;
- (c) comparing said expression profile to a reference threshold value;
- and
- (d) determining whether the human subject has clear cell RCC or papillary RCC based on altered expression of SEQ ID NOS:
- 1-24 relative to the reference threshold value;
- wherein increased expression of SEQ ID NOS:
- 3, 5-7, 9, 12 and 24 is indicative of the presence of clear cell RCC;
- and wherein increased expression of SEQ ID NOS:
- 1, 2, 4, 8, 10, 11 and 13-23 is indicative of the presence of papillary RCC.
Dependencies are inferred from the claim text.